Enliven Therapeutics (ELVN) Times Interest Earned (2019 - 2026)
Enliven Therapeutics (ELVN) reported Times Interest Earned of -$267.53 for Q1 2026, up 29.94% on a YoY basis from -$205.89 in Q1 2025, and up 8.7% sequentially from -$293.03 in Q4 2025.
Enliven Therapeutics (ELVN) Times Interest Earned (2019 - 2026) Analysis & Trends
Enliven Therapeutics (ELVN) has 8 years of Times Interest Earned data on file, last reported at -$267.53 in Q1 2026.
- For the quarter ending Q1 2026, Times Interest Earned rose 29.94% year-over-year to -$267.53; the trailing twelve-month figure through Mar 2026 stood at -$332.72 (up 10.07% YoY), and the FY2025 full-year result was -$4.3, down 184.81% from the prior year.
- Times Interest Earned improved to -$267.53 in Q1 2026, from -$293.03 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$0.52 in Q4 2022 to a low of -$820.9 in Q1 2023.
- A 5-year average of -$218.6 and a median of -$176.61 in 2023 frame the typical range for Times Interest Earned.
- Across the five-year window, Times Interest Earned soared 99.83% in 2022 and plunged 95889.91% in 2024, its largest moves.
- Tracing ELVN's Times Interest Earned over 5 years: stood at -$0.52 in 2022, then dropped by 22.51% to -$0.64 in 2023, then sank by 95889.91% to -$611.27 in 2024, then soared by 52.06% to -$293.03 in 2025, then climbed by 8.7% to -$267.53 in 2026.
- Business Quant data shows ELVN's Times Interest Earned at -$267.53 in Q1 2026, -$293.03 in Q4 2025, and -$48.82 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Enliven Therapeutics | 3.22 Bn | 3.22 Bn | - | -267.53 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -267.53 |
| Dec 31, 2025 | -293.03 |
| Sep 30, 2025 | -48.82 |
| Jun 30, 2025 | -46.55 |
| Mar 31, 2025 | -381.84 |
| Dec 31, 2024 | -611.27 |
| Sep 30, 2024 | -314.74 |
| Jun 30, 2024 | -289.45 |
| Mar 31, 2024 | -305.73 |
| Dec 31, 2023 | -0.64 |
| Sep 30, 2023 | -57.32 |
| Jun 30, 2023 | -176.61 |
| Mar 31, 2023 | -820.90 |
| Dec 31, 2022 | -0.52 |
| Sep 30, 2022 | -41.42 |
| Jun 30, 2022 | -20.26 |
| Mar 31, 2022 | -39.63 |
| Dec 31, 2021 | -311.61 |
| Sep 30, 2021 | -53.78 |
| Jun 30, 2021 | -3.43 |